Nexalin Technology, Inc. — Form S-1/A
Filed October 8, 2026 · analyzed by the Registration Agent
S-1/A
▼ Likely negative
significance 78/100
What the filing says
Nexalin Technology (market cap ~$14.7M) registered resale of up to 5,752,823 shares via an Any Market Purchase Agreement (AMPA) with Alumni Capital LP dated August 19, 2026. The AMPA provides a $15M committed equity facility allowing the company to sell shares at 92–97% of market price, plus 2% commitment fee (3% if delisted). Concurrently, Nexalin issued 80,645 common shares at $9.30/share and warrants to purchase 40,323 shares at $15/share. The company also acquired PONM Inc. for $1.3M in stock consideration and entered a pivotal clinical trial for its Gen-3 HALO insomnia device. Critical: Nexalin has substantial doubt about going concern, stockholders' equity of only $1.5M (below Nasdaq's $2.5M minimum), and accumulated deficit of $97.2M.
Why this rating
Large dilutive financing ($15M commitment ~102% of current market cap) on a distressed company with going-concern doubts and imminent Nasdaq delisting risk by January 4, 2027. Material relative to company size; trajectory-threatening if equity facility cannot be accessed or if delisting occurs.
Price action (we called it negative)
before filing · preread $4.00 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.